Diabetic heart disease: A clinical update

Table 1 Cardiovascular outcome trials of available antidiabetic drugs[131-150]

Drug	Trial name	Primary outcome	HR (95%CI)
Metformina	UKPDS legacy data[131]	MI	0.67 (0.51-0.89)
Gliclazide MR	ADVANCE[132]	CV death, MI, stroke	0.94 (0.84-1.06)
Pioglitazonea	Meta-analysis[133]	CV death, MI, stroke	0.83 (0.72-0.97)
Rosiglitazone	RECORD[134]	CV event or CV death	0.99 (0.85-1.16)
Acarbose (Chinese population)	ACE[135]	CV death, MI, stroke, UA, HF hospitalisation	0.98 (0.86-1.11)
Nateglinide	NAVIGATOR[136]	CV death, MI, stroke, HF hospitalisation	0.94 (0.82-1.09)
Saxagliptin	SAVOR-TIMI[137]	CV death, MI, ischaemic stroke	1.01 (0.88-1.15)
Alogliptin	EXAMINE[138]	CV death, MI, stroke, UA, and HF	0.98 (0.86-1.12)
Sitagliptin	TECOS[139]	CV death, MI, stroke, UA hospitalisation	0.98 (0.89-1.09)
Linagliptin vs glimepiride	CAROLINA[140]	CV death, MI, stroke	0.98 (0.84-1.14)
Empagliflozina	EMPA-REG[141]	CV death, MI, stroke	0.86 (0.74-0.99)
Canagliflozina	CANVAS[142]	CV death, MI, stroke	0.86 (0.75-0.97)
Dapagliflozin	DECLARE[143]	CV death, MI, ischaemic stroke	0.93 (0.84-1.03)
Ertugliflozin	VERTIS-CV[144]	CV death, MI, stroke	0.97 (0.85-1.11)
Lixisenatide	ELIXA[145]	CV death, MI, stroke, UA	1.02 (0.89-1.17)
Liraglutidea	LEADER[146]	CV death, MI, stroke	0.87 (0.78-0.97)
Semaglutidea	SUSTAIN-6[147]	CV death, MI, stroke	0.74 (0.58-0.95)
Exenatide	EXSCEL[148]	CV death, MI, stroke	0.91 (0.83-1.0)
Dulaglutidea	REWIND[149]	CV death, MI, stroke	0.88 (0.79-0.99)
Albiglutidea	HARMONY[150]	CV death, MI, stroke	0.78 (0.68-0.90)

HR: Hazard ratio; CI: Confidence interval; CV: Cardiovascular disease; MI: Myocardial infarction; UA: Unstable angina; HF: Heart Failure.

^aP < 0.05.